Global Blood Therapeutics Inc - Company Profile
Powered by 
All the data and insights you need on Global Blood Therapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Global Blood Therapeutics Inc Strategy Report
- Understand Global Blood Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Global Blood Therapeutics Inc (GBT), a subsidiary of Pfizer Inc, is a clinical-stage biopharmaceutical company. The company discovers and develops oxbryta (voxelotor), inclacumab and GBT601. Its products are used for the treatment of various therapeutic areas which includes sickle cell disease (SCD), chronic vaso-occlusive crisis (VOC) prevention, acute VOC re-admission prevention and hemolytic anemia. GBT offers products in tablet form for both children and adults under the brand name Oxbryta. The company also focuses on the development of therapies that are in preclinical clinical stages for the treatment of acute and chronic hypoxemic pulmonary disorders. GBT is headquartered in South San Francisco, California, the US.
Headquarters
United States of America
Address
181 Oyster Point Boulevard, South San Francisco, California, 94080
No of Employees
457
Industry
Pharmaceuticals and Healthcare
Revenue (2021)
$194.7M
Global Blood Therapeutics Inc premium industry data and analytics
Competitor Comparison
| Key Parameters | Global Blood Therapeutics Inc | Bristol-Myers Squibb Co | Emmaus Medical Inc | Medunik USA Inc | Novartis Pharmaceuticals Corp |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | South San Francisco | Princeton | Torrance | Rosemont | East Hanover |
| State/Province | California | New Jersey | California | Pennsylvania | New Jersey |
| No. of Employees | 457 | 34,100 | - | - | - |
| Entity Type | Private | Public | Private | Private | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward